Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Pyridyl-pyrimidine benzimidazole derivatives as potent, selective, and orally bioavailable inhibitors of Tie-2 kinaseVictor J Cee, Alan C Cheng, Karina Romero, et al.
Journal of Medicinal Chemistry|March 4, 2008
Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesisDaniel S La, Julie Belzile, James V Bready, et al.
Journal of Medicinal Chemistry|January 27, 2007
Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinaseVictor J Cee, Brian K Albrecht, Stephanie Geuns-Meyer, et al.
Journal of Medicinal Chemistry|January 27, 2007
Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitorBrian L Hodous, Stephanie D Geuns-Meyer, Paul E Hughes, et al.
Journal of Medicinal Chemistry|April 23, 2008
Discovery and optimization of triazolopyridazines as potent and selective inhibitors of the c-Met kinaseBrian K Albrecht, Jean-Christophe Harmange, David Bauer, et al.
Journal of Medicinal Chemistry|April 20, 2013
Rational design and binding mode duality of MDM2-p53 inhibitorsFelix Gonzalez-Lopez de Turiso, Daqing Sun, Yosup Rew, et al.
Journal of Medicinal Chemistry|March 8, 2014
Novel inhibitors of the MDM2-p53 interaction featuring hydrogen bond acceptors as carboxylic acid isosteresAna Z Gonzalez, Zhihong Li, Hilary P Beck, et al.
Journal of Medicinal Chemistry|November 11, 2014
Discovery of AM-7209, a potent and selective 4-amidobenzoic acid inhibitor of the MDM2-p53 interactionYosup Rew, Daqing Sun, Xuelei Yan, et al.
Journal of Medicinal Chemistry|April 25, 2012
Structure-based design of novel inhibitors of the MDM2-p53 interactionYosup Rew, Daqing Sun, Felix Gonzalez-Lopez De Turiso, et al.
Pageof 4